Praxis Precision Medicines Valuation Multiples

Praxis Precision Medicines Overview

About Praxis Precision Medicines

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Founded

2015

HQ

Employees

168

Website

praxismedicines.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $1M

EBITDA: ($349M)

EV

$9B

Valuation Multiples

Multiples.vc

Start free trial

Praxis Precision Medicines Financials

Praxis Precision Medicines reported last 12-month revenue of $1M and negative EBITDA of ($349M).

In the same LTM period, Praxis Precision Medicines generated $1M in gross profit, ($349M) in EBITDA losses, and had net loss of ($329M).

Praxis Precision Medicines P&L

In the most recent fiscal year, Praxis Precision Medicines reported revenue of — and EBITDA of ($326M).

Praxis Precision Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX

Praxis Precision Medicines Stock Performance

Praxis Precision Medicines has current market cap of $9B, and enterprise value of $9B.

Praxis Precision Medicines' stock price is $336.67.

Praxis Precision Medicines Valuation Multiples

Praxis Precision Medicines trades at 6567.4x EV/Revenue multiple, and (26.0x) EV/EBITDA.

Praxis Precision Medicines Financial Valuation Multiples

As of March 21, 2026, Praxis Precision Medicines has market cap of $9B and EV of $9B.

Equity research analysts estimate Praxis Precision Medicines' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Praxis Precision Medicines has a P/E ratio of (28.4x).

Praxis Precision Medicines Margins & Growth Rates

Praxis Precision Medicines' revenue in the last 12 month grew by 4944%.

Praxis Precision Medicines' revenue per employee in the last FY averaged $0.0M.

Praxis Precision Medicines' rule of 40 is (20345%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Praxis Precision Medicines' rule of X is (12929%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Praxis Precision Medicines Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Praxis Precision Medicines M&A Activity

Praxis Precision Medicines acquired XXX companies to date.

Last acquisition by Praxis Precision Medicines was on XXXXXXXX, XXXXX. Praxis Precision Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Praxis Precision Medicines Investment Activity

Praxis Precision Medicines invested in XXX companies to date.

Praxis Precision Medicines made its latest investment on XXXXXXXX, XXXXX. Praxis Precision Medicines invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).